insights_auto
Why is 4507 up 3,83%?
Dive Deeperchevron_right
4507:TYO
Shionogi & Co Ltd
JP¥2.763,00
arrow_upward
+3,83%(+102,00) 1D
6 ຕ.ລ., 15 ໂມງ 30 ນາທີ 00 ວິນາທີ GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4507...
Open
JP¥2.694
High
JP¥2.763
Low
JP¥2.686
Mkt. cap
2,46 ລ້ານລ້ານ
Avg. vol.
2,75 ລ້ານ
Volume
4,59 ລ້ານ
Dividend
2,57%
Quarterly dividend
JP¥18
Ex-dividend date
29 ກ.ຍ. 2026
P/E ratio
8,92
52-wk high
JP¥3.758
52-wk low
JP¥2.392
EPS
JP¥310
Shares outstanding
314,50 ລ້ານ
No. of employees
6 ພັນ
Open
JP¥2.694
High
JP¥2.763
Low
JP¥2.686
Mkt. cap
2,46 ລ້ານລ້ານ
Avg. vol.
2,75 ລ້ານ
Volume
4,59 ລ້ານ
Dividend
2,57%
Quarterly dividend
JP¥18
Ex-dividend date
29 ກ.ຍ. 2026
P/E ratio
8,92
52-wk high
JP¥3.758
52-wk low
JP¥2.392
EPS
JP¥310
Shares outstanding
314,50 ລ້ານ
No. of employees
6 ພັນ
News stories
From web sources and news partners
Fierce Pharma
·
1 ມື້ກ່ອນ
Shionogi strikes $2B deal for IntraBio hot off FDA label expansion
WSJ
·
1 ມື້ກ່ອນ
Shionogi to Acquire IntraBio for $2 Billion
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
About Shionogi & Co Ltd
CEOIsao Teshirogi
Employees6,22 ພັນ
Founded1878
Headquarters-
SectorPharmaceutical industry
Websiteshionogi.com